HCV/HIV- | HCV- | HIV- | P-value* | ||
---|---|---|---|---|---|
Coinfected | Monoinfected | Monoinfected | HCV/HIV | HCV/HI | |
N = 79 | N = 93 | N = 30 | vs HCV | V vs HIV | |
Site (n, %) | <0.001 | <0.001 | |||
HUP | 2 (3%) | 35 (38%) | 0 (0%) | ||
PPMC | 35 (44%) | 20 (22%) | 1 (3%) | ||
PVAMC | 42 (53%) | 38 (41%) | 29 (97%) | ||
Age (Median, IQR) | 55 (43–64) | 57.5 (53.5-61) | 54 (51–60) | 0.04† | NS† |
Sex (n, %) | NS | NS | |||
Male | 68 (86%) | 77 (83%) | 28 (93%) | ||
Female | 11 (14%) | 16 (17%) | 2 (7%) | ||
Race (n, %) | 0.001 | NS | |||
Caucasian | 9 (11%) | 35 (38%) | 5 (17%) | ||
Black | 64 (81%) | 50 (54%) | 24 (80%) | ||
Hispanic | 4 (5%) | 3 (3%) | 0 (0%) | ||
Other | 2 (3%) | 2 (2%) | 1 (3%) | ||
BMI (kg/m2) | 25.0 | 29.2 | 27.2 | <0.001† | 0.05† |
Median (IQR) | (22.5-29.0) | (25.5-33.2) | (25.0-33.2) | ||
Current smoker (n, %) | 29 (37%) | 37 (40%) | 9 (30%) | NS | NS |
HCV Treatment (n, %) | 0.01 | N/A | |||
Current | 4 (5%) | 17 (18%) | 0 (0%) | ||
Past | 22 (28%) | 31 (33%) | 0 (0%) | ||
Never | 53 (67%) | 45 (48%) | 30 (100%) | ||
HCV Genotype (n, %) | NS | N/A | |||
1 (A or B) | 70 (89%) | 60 (65%) | 0 (0%) | ||
2 | 1 (1%) | 5 (5%) | 0 (0%) | ||
3 | 1 (1%) | 4 (4%) | 0 (0%) | ||
HCV RNA (IU/mL) | 1.37 | 0.62 | N/A | 0.02† | N/A |
Median in million (IQR) | (0.44-4.63) | (0.03-2.70) | |||
CD4 count (cells/mm3) | 474 | N/A | 480 | N/A | NS† |
Median (IQR) | (358–666) | (295–673) | |||
Antiretroviral | 67 (85%) | 0 (%) | 26 (87%) | N/A | NS |
therapy (n, %) | |||||
Previous arthritis diagnosis‡ (n, %) | 37 (40%) | 28 (35%) | 8 (27%) | NS | NS |
Analgesic medication use (n, %) | NS | NS | |||
Any | 41 (52%) | 49 (53%) | 20 (67%) | ||
Opiate | 15 (19%) | 15 (16%) | 4 (13%) | ||
Gabapentin | 17 (22%) | 11 (12%) | 8 (27%) | ||
NSAIDs | 21 (27%) | 23 (25%) | 10 (33%) | ||
Tylenol | 10 (13%) | 18 (19%) | 9 (30%) |